LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus
C. Arriens, A. Askanase, R. Furie, Eric F Morand, Ronald Van Vollenhoven, Kevin Connors, M. Davey, N. Delev, V. Shah, A. Stevens, Thomas L. Wegman, C. Hobar
{"title":"LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus","authors":"C. Arriens, A. Askanase, R. Furie, Eric F Morand, Ronald Van Vollenhoven, Kevin Connors, M. Davey, N. Delev, V. Shah, A. Stevens, Thomas L. Wegman, C. Hobar","doi":"10.1136/lupus-2023-kcr.254","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":359413,"journal":{"name":"E-Poster Presentation","volume":"258 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"E-Poster Presentation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/lupus-2023-kcr.254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
